HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
RGEN
Repligen Corporation
RGEN lost money over the past year, so it has no meaningful PE right now. Analysts expect earnings to recover.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
RGEN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Healthy | |
| Strong |
RGEN's revenue, profitability, cash flow and balance sheet are all currently healthy.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
RGEN PE Valuation
RGEN has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
RGEN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Strong growth | |
| Weakening | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for RGEN, but weaker profitability.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
RGEN has the stronger earnings trend. Trailing diluted EPS is down 257% for HIMS versus RGEN up 38%.
RGEN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.43 | -16% |
| Q3 2022 | $2.90 | +38% |
| Q2 2022 | $2.77 | +55% |
| Q1 2022 | $2.53 | +74% |
| Q4 2021 | $2.24 | +102% |
| Q3 2021 | $2.10 | +156% |
| Q2 2021 | $1.79 | +209% |
| Q1 2021 | $1.45 | +222% |
| Q4 2020 | $1.11 | +152% |
RGEN's earnings per share have climbed steadily: $2.90 over the past year, up 38% from the year before, and higher year over year every quarter since late 2020.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over RGEN on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over RGEN on profitability, with a higher operating margin.
RGEN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $209.3M | +11% |
| Q2 2026 | $204.1M | +12% |
| Q1 2026 | $194.3M | +15% |
| Q4 2025 | $197.9M | +18% |
| Q3 2025 | $188.8M | +22% |
| Q2 2025 | $182.4M | +15% |
| Q1 2025 | $169.2M | +10% |
| Q4 2024 | $167.5M | +0.6% |
RGEN's revenue has grown year over year for nine quarters in a row: $209M last quarter, up 11% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -14% | -23 points |
| Q2 2026 | 6.8% | -0.8 points |
| Q1 2026 | 8.2% | +4.3 points |
| Q4 2025 | 9% | +31 points |
| Q3 2025 | 8.9% | +14 points |
| Q2 2025 | 7.6% | +4.2 points |
| Q1 2025 | 3.9% | +1.4 points |
| Q4 2024 | -22% | -28 points |
RGEN's operating margin was −14% last quarter, down 23 points from the same quarter a year ago, near the bottom of its range since 2019.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over RGEN on cash flow, with more consistent year-over-year improvement.
RGEN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $38.2M | -12% |
| Q2 2026 | $27.4M | +28% |
| Q1 2026 | $23.6M | +106% |
| Q4 2025 | $17.6M | -48% |
| Q3 2025 | $43.4M | +2.5% |
| Q2 2025 | $21.5M | -42% |
| Q1 2025 | $11.4M | -69% |
| Q4 2024 | $33.6M | +87% |
RGEN generated $107M in free cash flow over the past year, down 3% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over RGEN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
RGEN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.1% | -80K shares |
| 1 year | -1.4% | -810K shares |
RGEN has 57M diluted shares, down 1.4% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
RGEN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.8x | Net Cash |
| Q2 2026 | -0.4x | Net Cash |
| Q1 2026 | -0.3x | Net Cash |
| Q4 2025 | -0.2x | Net Cash |
| Q3 2025 | -2.7x | Net Cash |
| Q2 2025 | -14.0x | Net Cash |
| Q1 2025 | -17.8x | Net Cash |
| Q4 2024 | -21.9x | Net Cash |
RGEN has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
RGEN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 53.2 | Neutral |
| Stochastic | 48.9 | Neutral |
RGEN's weekly RSI is 53 (neutral) and its Stochastic is 49 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
RGEN PE vs Healthcare Sector
| Metric | RGEN | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
RGEN has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
RGEN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $176.8 | 5.8% below |
| 20 week MA | $166.0 | 0.3% above |
| 50 week MA | $147.6 | 13% above |
| 100 week MA | $142.8 | 17% above |
| 200 week MA | $152.1 | 9.5% above |
RGEN has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
RGEN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $92.2 | $195.7 | +112% |
| 2021 | $195.7 | $264.7 | +35% |
| 2022 | $264.7 | $167.5 | -37% |
| 2023 | $167.5 | $179.8 | +7.3% |
| 2024 | $179.8 | $145.5 | -19% |
| 2025 | $145.5 | $166.2 | +14% |
| 2026 YTD | $166.2 | $166.5 | +0.2% |
RGEN has the edge over HIMS on returns for 2026, with the stronger performance.